Disturbed carnitine regulation in chronic heart failure - Increased plasma levels of palmitoyl-carnitine are associated with poor prognosis

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 1892-1899

  Ueland, Thor ^a,c   Svardal, Asbjørn ^d   Øie, Erik ^a,b   Askevold, Erik T ^a   Nymoen, Ståle H ^a,c   Bjørndal, Bodil ^d   Dahl, Christen P ^a,b   Gullestad, Lars ^a,b,c   Berge, Rolf K ^d   Aukrust, Pål ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Carnitine; Heart failure; Prognosis

Indexed keywords

ACETYLCARNITINE; AMINO ACID DERIVATIVE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARNITINE; GAMMA BUTYROBETAINE; OCTANOYLCARNITINE; PALMITOYLCARNITINE; PROPIONYLCARNITINE; TRIMETHYLLYSINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID METABOLISM; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CARNITINE METABOLISM; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART TRANSPLANTATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; PALMITOYL CARNITINE BLOOD LEVEL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

CARNITINE; HEART FAILURE; PROGNOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; CARNITINE; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PALMITOYLCARNITINE; PROGNOSIS;

EID: 84883280100     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.04.150     Document Type: Article

References (29)

1. S. Neubauer The failing heart - an engine out of fuel N Engl J Med 356 2007 1140 1151
2. W.C. Stanley, F.A. Recchia, and G.D. Lopaschuk Myocardial substrate metabolism in the normal and failing heart Physiol Rev 85 2005 1093 1129
3. B.M. van, F.A. van Nieuwenhoven, and V. van d Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res 81 2009 420 428
4. A.M. Evans, and G. Fornasini Pharmacokinetics of L-carnitine Clin Pharmacokinet 42 2003 941 967
5. F.B. Stephens, D. Constantin-Teodosiu, and P.L. Greenhaff New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle J Physiol 581 2007 431 444
6. T.L. Broderick, H.A. Quinney, and G.D. Lopaschuk Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart J Biol Chem 267 1992 3758 3763
7. S. Abdel-aleem, M. Sayed-Ahmed, M.A. Nada, S.C. Hendrickson, L.J. St, and J.E. Lowe Stimulation of non-oxidative glucose utilization by L-carnitine in isolated myocytes J Mol Cell Cardiol 27 1995 2465 2472
8. M. Calvani, E. Reda, and E. rrigoni-Martelli Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions Basic Res Cardiol 95 2000 75 83
9. J.T. Whitmer Energy metabolism and mechanical function in perfused hearts of Syrian hamsters with dilated or hypertrophic cardiomyopathy J Mol Cell Cardiol 18 1986 307 317
10. C.E. Zaugg, M. Spaniol, and P. Kaufmann Myocardial function and energy metabolism in carnitine-deficient rats Cell Mol Life Sci 60 2003 767 775
11. S.R. Bergmann, P. Herrero, and R. Sciacca Characterization of altered myocardial fatty acid metabolism in patients with inherited cardiomyopathy J Inherit Metab Dis 24 2001 657 674
12. K. Choong, J.T. Clarke, E. Cutz, R.J. Pollit, and S.E. Olpin Lethal cardiac tachyarrhythmia in a patient with neonatal carnitine-acylcarnitine translocase deficiency Pediatr Dev Pathol 4 2001 573 579
13. L.J. Waber, D. Valle, C. Neill, S. DiMauro, and A. Shug Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport J Pediatr 101 1982 700 705
14. V. Regitz, A.L. Shug, and E. Fleck Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases Am J Cardiol 65 1990 755 760
15. Y. Masumura, A. Kobayashi, and N. Yamazaki Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure Jpn Circ J 54 1990 1471 1476
16. V. Soukoulis, J.B. Dihu, and M. Sole Micronutrient deficiencies an unmet need in heart failure J Am Coll Cardiol 54 2009 1660 1673
17. G. Vescovo, B. Ravara, V. Gobbo, and L.L. Dalla Inflammation and perturbation of the l-carnitine system in heart failure Eur J Heart Fail 7 2005 997 1002
18. W. El-Aroussy, A. Rizk, G. Mayhoub, S.A. Aleem, S. El-Tobgy, and M.S. Mokhtar Plasma carnitine levels as a marker of impaired left ventricular functions Mol Cell Biochem 213 2000 37 41
19. L. Vernez, M. Wenk, and S. Krahenbuhl Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/electrospray ionization ion trap tandem mass spectrometry Rapid Commun Mass Spectrom 18 2004 1233 1238
20. T. Ueland, C.P. Dahl, and L. Gullestad Circulating levels of non-phosphorylated uncarboxylated matrix gla protein are associated with disease severity in patients with chronic heart failure Clin Sci (Lond) 121 2011 119 127
21. M.J. Pencina, R.B. D'Agostino, and R.S. Vasan Statistical methods for assessment of added usefulness of new biomarkers Clin Chem Lab Med 48 2010 1703 1711
22. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
23. L. Gullestad, T. Ueland, and J.G. Fjeld Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study Circulation 112 2005 3408 3414
24. E. Øie, T. Ueland, and C.P. Dahl Fatty acid composition in chronic heart failure: Low circulating eicosatetraenoic acid and high vaccenic acid are associated with disease severity and predict mortality J Int Med 270 2011 263 272
25. N. Andrieu-Abadie, J.P. Jaffrezou, S. Hatem, G. Laurent, T. Levade, and J.J. Mercadier L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation FASEB J 13 1999 1501 1510
26. R. Ferrari, E. Merli, G. Cicchitelli, D. Mele, A. Fucili, and C. Ceconi Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review Ann N Y Acad Sci 1033 2004 79 91
27. R. Ferrari, and G.F. De The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure J Card Fail 3 1997 217 224
28. V. Regitz, M. Muller, and S. Schuler Carnitine metabolism - changes in the end stage of dilated cardiomyopathy and ischemic heart muscle disease Z Kardiol 76 Suppl. 5 1987 1 8
29. C.R. Bruce, A.J. Hoy, and N. Turner Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance Diabetes 58 2009 550 558